Warning! GuruFocus detected
1 Severe warning sign
with FULC.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Fulcrum Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3596161097
Compare
Compare
Traded in other countries / regions
FULC.USA Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
2019-07-18Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.93 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.23 | |||||
| Beneish M-Score | 20.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 33.5 | |||||
| 3-Year EBITDA Growth Rate | 49 | |||||
| 3-Year EPS without NRI Growth Rate | 61.9 | |||||
| 3-Year FCF Growth Rate | 74 | |||||
| 3-Year Book Growth Rate | -4.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -99.59 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.63 | |||||
| 9-Day RSI | 48.95 | |||||
| 14-Day RSI | 44.21 | |||||
| 3-1 Month Momentum % | -18.68 | |||||
| 6-1 Month Momentum % | 15.26 | |||||
| 12-1 Month Momentum % | -61.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.63 | |||||
| Quick Ratio | 22.63 | |||||
| Cash Ratio | 21.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.9 | |||||
| Shareholder Yield % | 1.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -24.79 | |||||
| Net Margin % | -12.16 | |||||
| FCF Margin % | -3.12 | |||||
| ROE % | -3.98 | |||||
| ROA % | -3.67 | |||||
| ROIC % | -125.55 | |||||
| 3-Year ROIIC % | -7539.41 | |||||
| ROC (Joel Greenblatt) % | -182.2 | |||||
| ROCE % | -7.86 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.55 | |||||
| PB Ratio | 0.71 | |||||
| Price-to-Tangible-Book | 0.71 | |||||
| EV-to-EBIT | 3.12 | |||||
| EV-to-Forward-EBIT | -1.25 | |||||
| EV-to-EBITDA | 3.39 | |||||
| EV-to-Forward-EBITDA | -1.27 | |||||
| EV-to-Revenue | -0.77 | |||||
| EV-to-Forward-Revenue | 3.67 | |||||
| EV-to-FCF | 27.79 | |||||
| Price-to-GF-Value | 0.08 | |||||
| Price-to-Net-Current-Asset-Value | 0.75 | |||||
| Price-to-Net-Cash | 0.78 | |||||
| Earnings Yield (Greenblatt) % | 32.05 | |||||
| FCF Yield % | -1.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FULC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fulcrum Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80 | ||
| EPS (TTM) ($) | -0.22 | ||
| Beta | 2.67 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 95.31 | ||
| 14-Day RSI | 44.21 | ||
| 14-Day ATR ($) | 0.235881 | ||
| 20-Day SMA ($) | 3.2035 | ||
| 12-1 Month Momentum % | -61.74 | ||
| 52-Week Range ($) | 2.78 - 10.13 | ||
| Shares Outstanding (Mil) | 53.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fulcrum Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fulcrum Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fulcrum Therapeutics Inc Frequently Asked Questions
What is Fulcrum Therapeutics Inc(FULC)'s stock price today?
The current price of FULC is $3.21. The 52 week high of FULC is $10.13 and 52 week low is $2.78.
When is next earnings date of Fulcrum Therapeutics Inc(FULC)?
The next earnings date of Fulcrum Therapeutics Inc(FULC) is 2025-05-13 Est..
Does Fulcrum Therapeutics Inc(FULC) pay dividends? If so, how much?
Fulcrum Therapeutics Inc(FULC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers